

08 May 2007

8 May 2007

Maelor plc ('Maelor' or the 'Company')

Re-Admission, Conditional Placing and Acquisition

The Board of Maelor plc (AIM: MLR), the specialist critical care company, is pleased to announce that it has conditionally raised £8 million through a placing of 80,000,000 new ordinary shares of 10p (the 'Placing') by Noble & Company Limited, Maelor's nominated adviser and broker.

Geoff McMillan, Non-Executive Chairman, Tim Wright, Chief Executive Officer, Nigel Goldsmith, Finance Director, Ann Hardy, Executive Director and John Gregory, Non-Executive Director have all participated in the Placing.

First Admission and the commencement of dealings in relation to the 70,005,833 Existing Ordinary Shares and New VCT/EIS Shares will take place today. It is expected that Second Admission and the commencement of dealings in relation to the 44,275,000 Protected VCT Shares and Non-VCT Shares will occur at 8am on 9 May 2007 and that Third Admission and commencement of dealings in relation to 10,000,000 Consideration Shares will occur at 8am on 10 May 2007. It is expected that completion of the acquisition of Acorus Therapeutics Limited will occur immediately following Third Admission.

Following completion of the acquisition of Acorus Therapeutics Limited, the Company will have 124,280,833 ordinary shares of 10p in issue.

Tim Wright, CEO of Maelor said:

'The acquisition of Acorus is a transforming transaction for Maelor, creating a strong, profitable business with positive cash flow. The integration risks, costs and distractions are minimal due to the virtual nature of Acorus and the combined product portfolios offer a high degree of synergy in terms of customer base and distribution channels. We now have a product portfolio and pipeline capable of delivering strong future growth.'

- Ends -